Showing results (31-40 of 58) with videos related to
Sort By:
Pageof 6
Alimentary Pharmacology & Therapeutics|November 20, 2018
Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse riskYao-Chun Hsu, Mindie H Nguyen, Lein-Ray Mo, et al.Antiviral Therapy|February 4, 2012
Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensationYao-Chun Hsu, Lein-Ray Mo, Chi-Yang Chang, et al.Journal of Gastroenterology and Hepatology|January 26, 2017
Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapyYao-Chun Hsu, Lein-Ray Mo, Chi-Yang Chang, et al.BMC Gastroenterology|December 10, 2017
Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapyNai-Hsuan Chien, Yen-Tsung Huang, Chun-Ying Wu, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|March 29, 2016
Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative PatientsYao-Chun Hsu, Lein-Ray Mo, Chi-Yang Chang, et al.Clinical and Molecular Hepatology|October 17, 2024
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trialYao-Chun Hsu, Chi-Yi Chen, Cheng-Hao Tseng, et al.Journal of Hepatology|December 11, 2012
Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosisChih-Wen Lin, Chih-Che Lin, Lein-Ray Mo, et al.Plos One|September 15, 2015
Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected PatientsChi-Chieh Yang, Wei-Lun Tsai, Wei-Wen Su, et al.The Lancet. Infectious Diseases|February 1, 2021
Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trialYao-Chun Hsu, Chi-Yi Chen, I-Wei Chang, et al.Liver International : Official Journal of the International Association for the Study of the Liver|September 17, 2016
Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patientsTung-Hung Su, Tsung-Hui Hu, Chi-Yi Chen, et al.Pageof 6